Lim Haoyuan, Mathew Christopher, Wong Suei Nee, Liu Christopher W
Division of Anesthesiology and Perioperative Medicine, Singapore General Hospital, Singapore.
National University of Singapore, Singapore.
J Clin Anesth. 2023 Oct 28;92:111304. doi: 10.1016/j.jclinane.2023.111304.
The efficacy of the erector spinae plane block (ESPB) has been demonstrated in several meta-analyses and it is increasingly being used in clinical practice. However, its mechanism of action is still not fully elucidated. Although initial anatomical studies have suggested the spread of the injectate into the paravertebral space as the main mechanism of action, more recent studies have not consistently demonstrated this. This systematic review was conducted to determine the overall proportion and extent of injectate spread following a thoracic ESPB.
PubMed, Scopus and EMBASE were searched. All studies that examined the injectate spread after a thoracic ESPB either through dissection or imaging were included. Excluded were all reviews, studies performed in paediatric patients and non-thoracic ESPBs. The primary outcome was the proportion of subjects with injectate spread in the erector spinae plane (ESP), paravertebral space (PVS), intercostal space (ICS) and epidural space (ES).
This review included 29 studies involving 113 cadavers and 79 volunteers. The proportion of subjects with injectate spread in the ESP, ICS, ES and PVS was 1 (95% confidence interval, 0.97-1), 0.51 (95% CI, 0.38-0.64), 0.38 (95% CI, 0.28-0.5) and 0.57 (95% CI, 0.49-0.64) respectively. The mean spread of injectate in the ESP, ICS, ES and PVS were 9.1 (95% CI, 8.0-10.3), 5.6 (95% CI, 4.0-7.3), 3.1 (95% CI, 1.0-5.3) and 3.5 (95% CI, 2.4-4.6) spinal levels respectively.
Based on this study, the thoracic ESPB consistently led to injectate spread into the ESP compartment but less reliable spread into the PVS, ES and ICS compartments. There is also preliminary evidence that an increased time to assessment may be associated with an increased spread of injectate into the PVS.
竖脊肌平面阻滞(ESPB)的疗效已在多项荟萃分析中得到证实,并且在临床实践中的应用越来越广泛。然而,其作用机制仍未完全阐明。尽管最初的解剖学研究表明注射剂扩散至椎旁间隙是主要作用机制,但最近的研究并未一致证实这一点。本系统评价旨在确定胸椎ESPB后注射剂扩散的总体比例和范围。
检索了PubMed、Scopus和EMBASE。纳入所有通过解剖或影像学检查胸椎ESPB后注射剂扩散情况的研究。排除所有综述、儿科患者研究和非胸椎ESPB研究。主要结局是注射剂扩散至竖脊肌平面(ESP)、椎旁间隙(PVS)、肋间间隙(ICS)和硬膜外间隙(ES)的受试者比例。
本综述纳入了29项研究,涉及113具尸体和79名志愿者。注射剂扩散至ESP、ICS、ES和PVS的受试者比例分别为1(95%置信区间,0.97 - 1)、0.51(95%CI,0.38 - 0.64)、0.